New Hope for Migraine Sufferers: Optinose Nasal Delivery of Sumatriptan Proves as Effective as Invasive Subcutantaneous Injection

WASHINGTON--(BUSINESS WIRE)--At the American Academy of Neurology Annual Meeting, Optinose, the Norwegian drug delivery specialists, today presented Phase I data that could lead to faster, effective and less invasive relief for migraine sufferers. The recently completed trial first demonstrated that Sumatriptan powder delivered intranasally using OptiNose’s 2nd generation device has a rapid onset of action and is as effective as subcutaneously administered Sumatriptan in preventing GTN Challenge Induced EEG changes in migraine sufferers.